A new test using eye fluid to predict the risk of uveal melanoma spreading
Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction
This study is looking for a gentler way to check if uveal melanoma, a type of eye cancer, might spread by testing proteins in the eye's fluid instead of using painful needle biopsies, helping doctors make better treatment choices while keeping patients safe.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Olmeda Biosciences LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11264264 on NIH RePORTER |
What this research studies
This research focuses on developing a less invasive method to predict the risk of metastasis in patients with uveal melanoma, a type of eye cancer. Instead of relying on painful needle biopsies, the study will analyze proteins found in the aqueous humor, the fluid in the front chamber of the eye. By using a safe procedure called AH paracentesis, researchers aim to identify specific protein markers that can indicate the likelihood of cancer spreading. This innovative approach seeks to enhance patient safety and improve treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uveal melanoma who are at risk of developing metastatic disease.
Not a fit: Patients with other types of cancer or those without a diagnosis of uveal melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more accurate way to predict metastatic risk in uveal melanoma patients, potentially leading to better treatment outcomes.
How similar studies have performed: While the approach of using aqueous humor for cancer risk prediction is innovative, similar proteomic analyses have shown promise in other cancer types, suggesting potential for success.
Where this research is happening
San Diego, United States
- Olmeda Biosciences LLC — San Diego, United States (Active)
Researchers
- Principal investigator: Xu, Liya — Olmeda Biosciences LLC
- Study coordinator: Xu, Liya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.